The Impact of Prior Stroke on the Outcome of Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Romain Didier, MD;

Slides:



Advertisements
Similar presentations
” سبحانك لا علم لنا إلا ما علمتنا إنك أنت العليم الحكيم “
Advertisements

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Trileaflet Aortic Valve. Management strategy for patients with chronic severe aortic regurgitation. Preoperative coronary angiography should be performed.
Impact of Anticoagulant and Anti-platelet Therapy on ICD Implant-Related Bleeding and Thromboembolic Events in Patients Enrolled in the NCDR ® ICD Registry.
Georg Nickenig, Universitatsklinikum Bonn, Germany Jan-Malte Sinning, Universitatsklinikum Bonn, Germany Jan Kovac, Glenfield Hospital, Leicester, UK Peter.
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
Lessons from TAVR Randomized Trials and Registries E Murat Tuzcu, MD Professor of Medicine Cleveland Clinic Financial disclosures: None PARTNER Executive.
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.
Use of Psoas Muscle Size as a Frailty Assessment Tool for Open and Transcatheter Aortic Valve Replacement Raghavendra Paknikar BS Jeffrey Friedman BS David.
THE RISE OF NEW TECHNOLOGIES FOR AORTIC VALVE STENOSIS: A PROPENSITY-SCORE ANALYSIS FROM TWO MULTICENTER REGISTRIES COMPARING SUTURELESS AND TRANS-CATHETER.
Percutaneous Aortic Valve Replacement without Predilatation for Symptomatic Severe Aortic Stenosis in High-Risk Patients Lev.
Conflicts of interests for Leif Thuesen, M.D.
Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC.
University Heart Center Hamburg
Corrado Tamburino, MD, PhD; Davide Capodanno, MD; Angelo Ramondo, MD; Anna Sonia Petronio, MD; Federica Ettori, MD; Gennaro Santoro, MD; Silvio Klugmann,
The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement Thomas.
1 Aortic Symposium 2010 Andrew W. ElBardissi, MD, MPH Sary F. Aranki, MD Lawrence H. Cohn, MD Stanton K. Shernan, MD Daniel J. FitzGerald, CCP, LP R. Morton.
Long-term Benefits of Surgical Pulmonary Embolectomy for Acute Pulmonary Embolus on Right Ventricular Function Brent Keeling MD 1, Bradley G. Leshnower.
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.
Trancatheter Aortic Valve Implantation (TAVI)
TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.
TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.
GENDER DISPARITIES AMONG PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT Michael A. Gaglia, Jr.; Michael J. Lipinski; Rebecca Torguson; Jiaxiang.
Martin B. Leon, MD on behalf of the PARTNER Investigators TCT 2010; Washington, DC; September 23, 2010 Transcatheter Aortic Valve Implantation in Inoperable.
Preoperative Hemoglobin A1c and the Occurrence of Atrial Fibrillation Following On-pump Coronary Artery Bypass surgery in Type-2 Diabetic Patients Akbar.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
Transcatheter Cardiovascular Therapeutics 2008 (October 12-17, 2008 · Washington, DC) First-in-Human Report: Initial Experience with a Stentless and Retrievable.
Vinod H. Thourani, MD on behalf of The PARTNER Trial Investigators
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Incidence and Outcomes of Valve Hemodynamic Deterioration in Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: A Report from the Society.
Longest Follow-up After Implantation of a Self-Expanding Repositionable Transcatheter Aortic Valve: Final Follow-up of the Evolut R CE Study Stephen Brecker,
Carotid Access for TAVR: An underappreciated approach?
TAVR in Patients With Chronic Kidney Disease
Outcomes in the CoreValve US High-Risk Pivotal Trial in Patients with a Society of Thoracic Surgeons Predicted Risk of Mortality Less than or Equal to.
New Data from The PARTNER Trial
Highlights From the SAPIEN 3 Experience in Intermediate-Risk Patients Vinod H. Thourani, MD on behalf of the PARTNER Trial Investigators Professor.
Costs of Periprocedural Complications in Patients Treated with Transcatheter Aortic Valve Replacement: Results from The PARTNER Trial Suzanne V. Arnold,
Raj R. Makkar, MD On behalf of The PARTNER Trial Investigators
Updates From NOTION: The First All-Comer TAVR Trial
Outcome of Left-Sided Cardiac Remodeling in Severe Aortic Stenosis Patients Undergoing Transcatheter Aortic Valve Implantation  Marco A. Magalhaes, MD,
Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.
TAVR – The Trans-carotid Approach
TAVR Requirements for the Cath Lab
Heart Valve Thrombosis & Neuro-Outcomes
MedStar Washington Hospital Center Cardiac Catheterization Conference
First Report of One-Year Outcomes of the REPRISE I Feasibility Study of the Repositionable Lotus Aortic Valve Replacement System Ian T. Meredith.
30-Day Safety and Echocardiographic Outcomes Following Transcatheter Aortic Valve Replacement with the Self-Expanding Repositionable Evolut PRO System.
Is There a Need to Address AF in patients Undergoing Valve Surgery?
First Report of Three-Year Outcomes With the Repositionable and Fully Retrievable Lotus™ Aortic Valve Replacement System: Results From the REPRISE I.
Early Outcomes with the Evolut R Repositionable Self-Expanding Transcatheter Aortic Valve in the United States Mathew Williams, MD, For the Evolut R US.
Giuseppe Tarantini MD, PhD
Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement Harold L. Dauerman, MD; Michael J. Reardon,
TAVI „Catch me if you can!“
The Impact of Live Case Transmission on Patient Outcomes during Transcatheter Aortic Valve Replacement: Results from the VERITAS Study Dr. Ron Waksman.
Vinod H. Thourani, MD on behalf of The PARTNER Trial Investigators
Insights from the NCDR® STS/ACC TVT Registry.
CoreValve Continued Access Study Shows Continued Improvement in 1-Year Outcomes With Self-Expanding Transcatheter Aortic Valve Replacement Steven J. Yakubov,
Axel Linke University of Leipzig Heart Center, Leipzig, Germany
Mohamed Eid Fawzy, FRCP, FACC, FESC October 6 University Cairo, EGYPT
Annual Outcomes With Transcatheter Valve Therapy
Risk of post-operative stroke in patients with known extra-cranial carotid artery disease undergoing Non-Cardiac Surgery Heart and Vascular.
Managing and Correcting a "Frozen" Leaflet after TAVR
University Heart Center Hamburg
Balloon-Expandable Transcatheter Valve System : OUS Data
Annual Outcomes With Transcatheter Valve Therapy
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
Procedural Characteristics
A. Procopi, N. Procopi, JP Collet, O. Barthelemy, P. Leprince, R
Presentation transcript:

The Impact of Prior Stroke on the Outcome of Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Romain Didier, MD; Edward Koifman, MD; Sarkis Kiramijyan, MD; SmitaI.Negi, MD; Ricardo O. Escarcega, MD; Nevin C. Baker, DO; Jiaxing Gai, MSPH; Rebecca Torguson, MPH; Petros Okubagzi, MD; Itsik Ben-Dor, MD; Lowell F. Satler, MD; Augusto D. Pichard, MD; Ron Waksman, MD MedStar Washington Hospital Center, Washington, DC

Romain DIDIER, MD The Impact of Prior Stroke on the Outcome of Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement FINANCIAL DISCLOSURE: No relevant financial relationship exists Presenter Disclosure Information Elements

Patients undergoing Transcatheter valve replacement (TAVR) with prior stroke may be at higher risk compared to the patients without prior stroke due to hemodynamic instability coagulation issues and impaired neurological reserve. A history of a prior stroke in patients undergoing Surgical Aortic Valve Replacement has been identified as an independent risk factor for post-procedural stroke. However, there are scarce data regarding incidence of post-procedural stroke and mortality in patients with prior stroke undergoing TAVR. Background

The present study aimed to evaluate the impact of prior Cerebro- vascular events in patients undergoing TAVR in regard to in- hospital outcomes and early and late mortality. Aims

Patients with severe aortic stenosis undergoing TAVR between May 2007 and March 2015 from the Washington Hospital Center were included and categorized to patients with and without prior stroke, defined as embolic, hemorrhagic stroke and transit ischemic attack. Baseline, procedural characteristics and in-hospital outcomes in accordance with the Valve Academic Research Consortium-2 consensus were prospectively collected during the screening, on admission, immediately post-procedure, and during follow-up. The 1-month and 1-year mortality were compared between the two groups. All patients with stroke had neurological evaluation and neuroimaging documentation (brain computer tomography or brain magnetic resonance imaging) Methods

Baseline characteristics No Prior Stroke (N=543) Prior Stroke (N=120) p Age, years, sd 83 ± ± BMI, sd ± ± NYHA class III or IV 90% (475)85.7% (102)0.18 Cardiovascular risk factor Hypertension 93.2% (506)95% (114)0.46 Diabetes 33.1% (179)34.2% (41)0.98 Insulin dependent diabetes 10.9% (59)10.8% (13)0.98 Hyperlipidemia 79.1% (427)84.9% (101)0.15 Current or prior smoking 33.6% (159)31.4% (33)0.66 Past medical history COPD 36.4% (197)27.5% (33)0.06 Renal insufficiency 43.8% (235)59% (69)0.003 History of cancer 26.2% (121)21.7% (20)0.36 Carotid artery disease 12.3% (56)67.8% (61)<0.001 Peripheral vascular disease 32.5% (171)42.9% (51)0.03 History of CAD 72.4% (323)83.8% (83)0.02 Prior CABG 31.7% (171)45% (54)0.005 Prior PCI 31.5% (169)26.9% (32)0.32 Prior MI 18.4% (97)20.2% (24)0.65 Prior valve surgery 4.9% (23)3.3% (3)0.78 Prior BAV 27.5% (135)37.8% (37)0.04 Multiple prior BAV 2.9% (13)12.8% (11)<0.001

Baseline characteristics No Prior Stroke (N=543)Prior Stroke (N=120)p Baseline rhythm History of Atrial fibrillation / Flutter 43.2% (234)35.8% (43)0.14 Pacemaker 25.1% (94)22% (20)0.54 Baseline ECG sinus rhythm 61.7% (255)66.3% (55)0.44 Baseline ECG Atrial fibrillation 19.7% (81)13.6% (11)0.2 Baseline antiplatelet and anticoagulation treatment Aspirin 83.3% (229)94.5% (69)0.02 Clopidogrel 46.9% (84)58.2 (32)0.14 Warfarin 37.6% (65)32% (16)0.47 Porcelain Aorta 7.2% (39)8.3% (10)0.66 Frailty 43% (101)47.2% (25)0.57 STS Score STS Score >8 52.2% (283)64.7% (77)0.013 STS Score, sd 8.8 ± ± Logistic Euro Score, sd 25.2 ± ± 27.8<0.001

Baseline cardiac computed tomography angiography, echocardiography, and catheterization. No Prior Stroke (N=543)Prior Stroke (N=120)p Cardiac CTA indices Severe ascending aorta calcification25.1% (74)41.5% (22)0.01 Severe aortic valve calcification39.1% (117)48.2% (27)0.2 Aortic valve area, mm 2, sd453.6 ± ± MLD right side, mm 2, sd 7.28 ± ± MLD left side, mm 2, sd 7.24 ± ± Echocardiographic indices LVEF, %, sd52.2 ± ± LVSDD, sd4.47 ± ± LVSSD, sd3.09 ± 0.93 ± LA diameter, sd4.53 ± ± AVA, cm 2, sd0.67 ± ± AVA Indexed, cm 2 /m 2, sd 1.85 ± ± Aortic Valve Max Velocity, m/s, sd 4.3 ± ± Mean Gradient, mmHg, sd47.3 ± ± Severe MR0.4% (2)1% (1)0.4 Severe RV dysfunction2.9% (14)1.9% (2)0.7 PASP, mmHg, sd45.5 ± ± Catheterization indices Three vessel disease (>50%)18.2% (62)31.7% (20)0.01 LAD >50% stenosis38.5% (134)59.4% (38)0.002

No Prior Stroke (N=543) Prior Stroke (N=120) p Anesthesia Conscious sedation71% (385)65% (78)0.19 General anesthesia29.5% (160)35.8% (43)0.17 Access Transfemoral access79.6% (432)70.8% (85)0.037 Transapical access17.3% (94)27.5% (33)0.01 Procedure Pre-TAVR BAV87.6% (475)84.7% (100)0.4 Rapid pacing97.8% (528)96.6% (114)0.5 Hypotension7% (38)7.5% (9)0.85 Post-TAVR balloon8.3% (39)3.8% (3.8)0.11 Intra-aortic balloon pump1.7% (5)2.5% (2)0.64 One valve deployed94.7% (514)94.2% (113)0.82 Type of valve Edwards Sapien Valve47.5% (261)57.3% (67)0.06 Edwards XT Valve20% (110)23.1% (27)0.46 Core Valve23.7% (130)16.2% (19)0.08 Procedural parameters

Mortality 18,3% 15,6% 22.5% 21.7% No prior stroke Prior stroke % 7.6%

In-hospital outcomes

No prior stroke (N=543)Prior stroke (N=120)p VARC-2 major vascular complications 10.5% (55)9.3% (11)0.7 VARC-2 life-threatening bleeding 7.5% (40)9.2% (11)0.5 New pacemaker implantation 8.4% (44)4.2% (5)0.12 New atrial fibrillation/flutter 13% (69)15.1% (18)0.54 Post-procedure hospital stay, median, IQR 5 ± 46 ± Post-procedure ICU stay, median, IQR 2 ± Bleeding and Hospital stay

This study supports the hypothesis that TAVR in patients with a history of stroke is safe. Although it is accompanied by higher rate of in-hospital minor stroke and acute kidney injury, it confers no impact on early or late mortality and even hospitalization length. Accordingly, patients with prior stroke should be not excluded from TAVR procedures due to this condition alone. Nevertheless, patients with prior stroke are at higher risk of and may require more care before, during and after the procedure. Conclusions